These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1493 related articles for article (PubMed ID: 27184250)

  • 41. Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.
    Lista S; Molinuevo JL; Cavedo E; Rami L; Amouyel P; Teipel SJ; Garaci F; Toschi N; Habert MO; Blennow K; Zetterberg H; O'Bryant SE; Johnson L; Galluzzi S; Bokde AL; Broich K; Herholz K; Bakardjian H; Dubois B; Jessen F; Carrillo MC; Aisen PS; Hampel H
    J Alzheimers Dis; 2015 Sep; 48 Suppl 1():S171-91. PubMed ID: 26402088
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improved multimodal prediction of progression from MCI to Alzheimer's disease combining genetics with quantitative brain MRI and cognitive measures.
    Reas ET; Shadrin A; Frei O; Motazedi E; McEvoy L; Bahrami S; van der Meer D; Makowski C; Loughnan R; Wang X; Broce I; Banks SJ; Fominykh V; Cheng W; Holland D; Smeland OB; Seibert T; Selbaek G; Brewer JB; Fan CC; Andreassen OA; Dale AM;
    Alzheimers Dement; 2023 Nov; 19(11):5151-5158. PubMed ID: 37132098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.
    Henriques AD; Benedet AL; Camargos EF; Rosa-Neto P; Nóbrega OT
    Exp Gerontol; 2018 Jul; 107():169-177. PubMed ID: 29307736
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dynamics of brain structure and cognitive function in the Alzheimer's disease neuroimaging initiative.
    Song X; Mitnitski A; Zhang N; Chen W; Rockwood K;
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):71-8. PubMed ID: 23123510
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease.
    Persson K; Barca ML; Eldholm RS; Cavallin L; Šaltytė Benth J; Selbæk G; Brækhus A; Saltvedt I; Engedal K
    Dement Geriatr Cogn Disord; 2017; 44(1-2):12-24. PubMed ID: 28614836
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.
    Grundman M; Petersen RC; Ferris SH; Thomas RG; Aisen PS; Bennett DA; Foster NL; Jack CR; Galasko DR; Doody R; Kaye J; Sano M; Mohs R; Gauthier S; Kim HT; Jin S; Schultz AN; Schafer K; Mulnard R; van Dyck CH; Mintzer J; Zamrini EY; Cahn-Weiner D; Thal LJ;
    Arch Neurol; 2004 Jan; 61(1):59-66. PubMed ID: 14732621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).
    Ellis KA; Szoeke C; Bush AI; Darby D; Graham PL; Lautenschlager NT; Macaulay SL; Martins RN; Maruff P; Masters CL; McBride SJ; Pike KE; Rainey-Smith SR; Rembach A; Robertson J; Rowe CC; Savage G; Villemagne VL; Woodward M; Wilson W; Zhang P; Ames D;
    Int Psychogeriatr; 2014 Apr; 26(4):543-54. PubMed ID: 24252258
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predicting the conversion of mild cognitive impairment to Alzheimer's disease based on the volumetric measurements of the selected brain structures in magnetic resonance imaging.
    Nesteruk M; Nesteruk T; Styczyńska M; Barczak A; Mandecka M; Walecki J; Barcikowska-Kotowicz M
    Neurol Neurochir Pol; 2015; 49(6):349-53. PubMed ID: 26652867
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment.
    Lacour A; Espinosa A; Louwersheimer E; Heilmann S; Hernández I; Wolfsgruber S; Fernández V; Wagner H; Rosende-Roca M; Mauleón A; Moreno-Grau S; Vargas L; Pijnenburg YA; Koene T; Rodríguez-Gómez O; Ortega G; Ruiz S; Holstege H; Sotolongo-Grau O; Kornhuber J; Peters O; Frölich L; Hüll M; Rüther E; Wiltfang J; Scherer M; Riedel-Heller S; Alegret M; Nöthen MM; Scheltens P; Wagner M; Tárraga L; Jessen F; Boada M; Maier W; van der Flier WM; Becker T; Ramirez A; Ruiz A
    Mol Psychiatry; 2017 Jan; 22(1):153-160. PubMed ID: 26976043
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel Blood Biomarkers that Correlate with Cognitive Performance and Hippocampal Volumetry: Potential for Early Diagnosis of Alzheimer's Disease.
    Hudd F; Shiel A; Harris M; Bowdler P; McCann B; Tsivos D; Wearn A; Knight M; Kauppinen R; Coulthard E; White P; Conway ME
    J Alzheimers Dis; 2019; 67(3):931-947. PubMed ID: 30689581
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detecting early preclinical Alzheimer's disease via cognition, neuropsychiatry, and neuroimaging: qualitative review and recommendations for testing.
    Belleville S; Fouquet C; Duchesne S; Collins DL; Hudon C
    J Alzheimers Dis; 2014; 42 Suppl 4():S375-82. PubMed ID: 25190629
    [TBL] [Abstract][Full Text] [Related]  

  • 55. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 57. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Secondary prevention of Alzheimer's dementia: neuroimaging contributions.
    Ten Kate M; Ingala S; Schwarz AJ; Fox NC; Chételat G; van Berckel BNM; Ewers M; Foley C; Gispert JD; Hill D; Irizarry MC; Lammertsma AA; Molinuevo JL; Ritchie C; Scheltens P; Schmidt ME; Visser PJ; Waldman A; Wardlaw J; Haller S; Barkhof F
    Alzheimers Res Ther; 2018 Oct; 10(1):112. PubMed ID: 30376881
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease.
    Levey A; Lah J; Goldstein F; Steenland K; Bliwise D
    Clin Ther; 2006 Jul; 28(7):991-1001. PubMed ID: 16990077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease.
    Wang X; Huang W; Su L; Xing Y; Jessen F; Sun Y; Shu N; Han Y
    Mol Neurodegener; 2020 Sep; 15(1):55. PubMed ID: 32962744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 75.